Corvidia Therapeutics has secured $60m in a Series B funding round to accelerate growth of its ongoing clinical programs, expand scientific and market access capabilities and explore new treatment areas.
Scientists from the University of Lincoln in the UK have created a new technique using nanotechnology which can make drugs more effective at reaching their target.
Tmunity Therapeutics, a biotherapeutics company focused on developing next-generation T cell immunotherapy, has raised new funding of $35m in a Series A investment from Kleiner Perkins and affiliates.
Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline.
Sandoz, a division of Novartis, and Pear Therapeutics have agreed to jointly commercialize and continue development of novel prescription digital therapeutics designed to treat disease and improve clinical outcomes for patients.
Novartis said that it will invest more than $100m to advance research and development of new antimalarials over the next five years.
Kalytera Therapeutics has announced the termination of its pre-clinical development programs in the treatment of bone disease to focus its resources on graft versus host disease (GVHD) and pain programs.
Inovio Pharmaceuticals has secured funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS).
Privately held clinical-stage biotechnology firm Orchard Therapeutics has agreed to acquire the rare disease gene therapy portfolio of GlaxoSmithKline (GSK).
Mylan has acquired an exclusive license to commercialize a biosimilar to Humira (adalimumab), developed by Fujifilm Kyowa Kirin Biologics, in Europe.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.